Scopio Labs secures $42 million Series D for AI-based blood cell analysis
Scopio Labs secures $42 million Series D for AI-based blood cell analysis
The Israeli startup's platform uses computational photography to provide digital imaging of thousands of cells, giving lab practitioners a full-field view of all regions of clinical interest on the sample at the highest resolution, supplanting the need for manual microscopy.
Scopio Labs, which develops full-field digital cell morphology imaging and analysis platforms, announced on Thursday the completion of its Series D funding round, raising $42 million. This round was led by Fortissimo Capital, with participation from existing investors. This Series D brings Scopio’s total fundraising to $130 million. Founded in 2015, by Itai Hayut (CEO) and Erez Naaman (CTO), Scopio employs 110 people, mostly in Israel.
Scopio’s platform uses computational photography to provide digital imaging of thousands of cells, giving lab practitioners a full-field view of all regions of clinical interest on the sample at the highest resolution, supplanting the need for manual microscopy. The company’s clinical AI-based decision support combined with full-field digital imaging, provides workflow efficiency in blood cell analysis designed to enhance remote consultation and collaboration, expedite decision-making, and bolster patient care.
"The manual microscope has been and continues to be an important tool for characterizing cells, including blood cells, for the past two hundred years. Once the sample is digitized, a whole world of possibilities opens up - starting with the possibility of remote diagnosis and continuing with computer vision-based systems that categorize the cells by type and assist the expert in making decisions," Hayut told Calcalist.
The next steps are even more exciting, as technology begins to exceed human capabilities: counting a quantity of cells that is ten or a hundred times greater than what a specialist can do alone, identifying cells that are currently considered rare and quantifying information about them for the first time, and gaining insights into how these cells in our bloodstream allow for the early detection and monitoring of diseases, including infections, anemia, and malignant diseases such as leukemia. All this is possible only through high-resolution imaging of the sample and the use of AI tools for data analysis. We are very proud that laboratories are adopting these tools that we are developing. The current fundraising will allow us to continue expanding our customer base and to complete the development of another analysis tool for blood tests."
